Patrick Ma lab presents research at ASCO meeting, Xiaoliang Wu wins Merit Award

Patrick Ma lab presents research at ASCO meeting, Xiaoliang Wu wins Merit Award

Patrick Ma, M.D., co-leader of the WVU Cancer Institute Sara Crile Allen & James Frederick Allen Comprehensive Lung Cancer Program and director of the Clinical Lung Cancer Program, and Xiaoliang Wu, M.D., Ph.D., postdoctoral research fellow in Dr. Ma’s lab, were featured presenters at the 2018 American Society of Clinical Oncology (ASCO) Annual Scientific Meeting this June.

In addition to serving in several leadership roles at the ASCO meeting, including member of the Educational Committee, tumor biology track leader of the Scientific Program Committee and session chair for the Tumor Biology Oral Abstract Session and an Education Session, Dr. Ma presented two talks – Linking Immune and Genomic Heterogeneity: Clinical and Biologic Implications and Novel Platforms and Clinical Applications for Noninvasive Molecular Testing. Both focused on topics at the forefront of modern cancer research – genomic profiling and immune repertoire profiling, and novel molecular diagnostic platforms, such as liquid biopsy and breath biopsy. His research titled PRC-2 epigenetic chromatin reprogramming in ALK-positive (ALK+) lung cancer initial emergence of precision drug resistance was also selected to be highlighted in a Poster Discussion Session during the meeting.

Dr. Wu won a 2018 Conquer Cancer Foundation of ASCO Merit Award based on his research presentation Mass spectrometry biomolecular omics profiling and imaging to dissect the initial emergence of molecular drug resistance in ALK-positive (ALK+) lung cancer, which was featured during a Poster Discussion Session. Using cutting-edge technology, he was able to pinpoint when drug resistance began at a molecular level in lung cancer cells that received precision therapy. His work identified tumor cell protein reprogramming as early as 7 days while the majority of tumor cells were being killed off by the precision therapy.

Dr. Wu also presented Whole exome sequencing (WES) to define the genomic landscape of young lung cancer patients during an Oral Abstract Session. In that research project he leveraged state-of-the-art, next-generation cancer genome sequencing technology to unravel the genomic mystery of why lung cancer occurs in young patients, under 45 years of age, often without any smoking history.

ASCO’s Annual Meeting brought together more than 40,000 oncology professionals from around the world to discuss state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field.

  • Individuals who advance women’s concerns can be nominated for Buswell Award

    The Council for Women's Concerns is accepting nominations for the Mary Catherine Buswell Award. This accolade, established in 1978, honors a person who has shown a dedication to the advancement of women. The award winner will receive $500 for travel, supplies, salary supplement or any other use commensurate with WVU policies. Nominations must be submitted by March 1.

    Read More

  • Blood drives to be held on Jan. 31, Feb. 5 and 15

    Blood drives to be held on Jan. 31, Feb. 5 and 15

    Every two seconds, someone needs blood, platelets, or plasma to survive. These patients depend on blood donors to roll up their sleeves and give the gift of life.

    Read More

  • WVU Cancer Institute recognizes Cervical Cancer Awareness Month

    WVU Cancer Institute recognizes Cervical Cancer Awareness Month

    The WVU Cancer Institute is joining organizations across the world to increase awareness of cervical cancer this January in recognition of Cervical Cancer Awareness Month. Cervical cancer diagnoses have increased the last 40 years as the result of many women getting regular Pap tests, which can find cervical precancerous cells before they become cancer.

    Read More